{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.8","upperLimit":"26.7","value":"13.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Treatment-refractory metastatic castration-resistant prostate cancer after recurrence or failure of docetaxel and prior treatment with abiraterone, enzalutamide, or any other androgen receptor-targeted agent","id":"OG000","title":"Metastatic Castration-resistant Prostate Cancer"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Day 1 up to approximately 2 years","title":"Percentage of Patients With Confirmed Prostate-specific Antigen Decline of ≥50% as Assessed According to Prostate Cancer Clinical Trials Working Group 3 Modified RECIST 1.1","type":"SECONDARY","unitOfMeasure":"percentage of participants"}